<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02752698</url>
  </required_header>
  <id_info>
    <org_study_id>XY3-DSRCS1507A01</org_study_id>
    <nct_id>NCT02752698</nct_id>
  </id_info>
  <brief_title>Domestic Surgical Robot Clinical Study</brief_title>
  <official_title>Safety and Feasible Study of Domestic Surgical Robot That Had Been Authorized to Enter the Clinical Trial Stage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Third Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Third Xiangya Hospital of Central South University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Central South University in collaboration with Tianjin University developed the first&#xD;
      domestically produced Chinese minimally invasive surgical (MIS) robot system which named&#xD;
      &quot;Micro Hand S&quot; in 2013. Recently, as the domestic surgical robot research project's main&#xD;
      section, this new MIS robot had been authorized to enter the clinical trial stage by the&#xD;
      Ethics Committee of the Third Xiangya Hospital at Central South University.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      One surgeon perform these surgical trials using the robot &quot;Micro Hand S&quot;. All of the patients&#xD;
      were followed for 12 months, and pre- and postoperative changes in blood route test and&#xD;
      hepatorenal function examination, surgery duration, hospital stay, total robotic setup time,&#xD;
      total robotic operation time, intraoperative blood loss, total postoperative drainage amount,&#xD;
      duration of bearing drainage tubes were recorded. In addition, the pre- and postoperative&#xD;
      changes in the pathological and functional outcomes were measured.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 1, 2015</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>intraoperative outcomes</measure>
    <time_frame>up to 1 week after operation</time_frame>
    <description>surgical procedure/operative time/console time/blood loss/conversion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>postoperative outcomes</measure>
    <time_frame>up to 1 month after operation</time_frame>
    <description>Time to first flatus/intake/hospital stay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>pathological outcomes</measure>
    <time_frame>up to 1 month after operation</time_frame>
    <description>resection margin/harvested lymph node/mesorectal grade</description>
  </primary_outcome>
  <primary_outcome>
    <measure>complication</measure>
    <time_frame>within 30 days after surgery</time_frame>
    <description>type of complication/grade of complication</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>functional outcomes</measure>
    <time_frame>at least12 months after operation</time_frame>
    <description>wexner/ipss/iief score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>recurrence</measure>
    <time_frame>at least 12 months after operation</time_frame>
    <description>local recurrence and metastasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>survival</measure>
    <time_frame>at least 12 months yesra after operation</time_frame>
    <description>disease free survival/overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of blood and biochemiacl</measure>
    <time_frame>within 1 month after operation</time_frame>
    <description>wbc/hgb/albumin/cea</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Gastric Ulcer With Perforation But Without Obstruction</condition>
  <condition>Colon Cancer</condition>
  <condition>Cholecystolithiasis</condition>
  <condition>Appendicitis</condition>
  <condition>Sleeve Gastrectomy</condition>
  <condition>Gastric Bypass</condition>
  <condition>Gastric Cancer</condition>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Micro Hand S robotic group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Micro Hand S robotic surgery group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>laparoscopic surgery</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>laparoscopic surgery group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>da Vinci robotic group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>da Vinci robotic robotic group</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Micro Hand S robotic surgery</intervention_name>
    <description>20-70 patients undergo Micro Hand S robotic surgeries</description>
    <arm_group_label>Micro Hand S robotic group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>laparoscopic surgery</intervention_name>
    <description>20-70 patients undergo laparoscopic surgeries</description>
    <arm_group_label>laparoscopic surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>da Vinci robotic surgery</intervention_name>
    <description>20-70 patients undergo da Vinci robotic surgeries</description>
    <arm_group_label>da Vinci robotic group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  diagnosis of gastric tumor, colorectal tumor, acute cholecystitis and ileocecal tumor&#xD;
             respectively&#xD;
&#xD;
          -  18years&lt;age&lt;65years&#xD;
&#xD;
          -  male or female&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients with a history of open abdominal surgery&#xD;
&#xD;
          -  unstable psychiatric illness&#xD;
&#xD;
          -  an inability or reluctance to cooperate during long-term follow-up&#xD;
&#xD;
          -  alcohol or drug addiction&#xD;
&#xD;
          -  or relatively high surgical risks, such as abnormal coagulation function or bad heart,&#xD;
             lung, liver and kidney function, were excluded from this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>shaihong zhu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Third Xiangya Hospital of Central South University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Third Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>June 15, 2015</study_first_submitted>
  <study_first_submitted_qc>April 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2016</study_first_posted>
  <last_update_submitted>March 29, 2021</last_update_submitted>
  <last_update_submitted_qc>March 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Appendicitis</mesh_term>
    <mesh_term>Stomach Ulcer</mesh_term>
    <mesh_term>Cholecystolithiasis</mesh_term>
    <mesh_term>Cholelithiasis</mesh_term>
    <mesh_term>Gallstones</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

